Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial-Reference-Cited by-同舟云学术

Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial

Published:2022-09 Issue: Volume: Page:
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Olivier Timothée,Powell Kerrington,Prasad Vinay

Publisher

Elsevier BV

Subject

Urology

Reference13 articles.

1. Prostate cancer;Rebello;Nat Rev Dis Primers,2021

2. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer;Sartor;N Engl J Med,2021

3. US Food and Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer. Silver Spring, MD: US FDA; 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer.

4. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial;Khalaf;Lancet Oncol,2019

5. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer;de Wit;N Engl J Med,2019

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two-to-One Randomization: Rarely Advisable;JCO Oncology Practice;2024-07-10

2. Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit;BJC Reports;2024-06-24

3. Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands;British Journal of Radiology;2024-05-11

4. 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers;Cancer Treatment Reviews;2024-04

5. Equal censoring but still informative: When the reasons for censoring differ between treatment arms;European Journal of Cancer;2024-04